Q-omics provides the consensus-scored KIAA0319L profile across patient tissues and cancer cell-line models. KIAA0319L expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, KIAA0319L is differentially expressed in 12, with the highest sampling consensus in KICH. Additionally, KIAA0319L RNA expression shows 20,372 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight LIHC, KICH, and ACC as cancer lineages where KIAA0319L shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for KIAA0319L — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes KIAA0319L survival associations across molecular data types. KIAA0319L RNA expression shows survival associations in the most cancer types (21), followed by mutation status (6) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible KIAA0319L RNA expression–survival associations across cancer types. High KIAA0319L expression shows unfavorable associations in LIHC, MESO and LGG, but favorable associations in KIRC, BRCA and LUAD. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for KIAA0319L RNA expression.
This table summarizes KIAA0319L tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 5. The strongest signals are observed in KICH for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for KIAA0319L. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. KIAA0319L shows lower tumor expression in KICH and higher tumor expression in LIHC, STAD, BLCA, BRCA and HNSC. The KICH box plot shows higher KIAA0319L RNA expression in normal versus tumor tissue (log2 FC = −1.025, t-test p < 0.001).
This table shows molecular features associated with KIAA0319L in patient tissues and cancer cell lines. In patient samples, KIAA0319L shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, KIAA0319L RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in PANCREAS and UPPER_AERODIGESTIVE_TRACT.
